Publications by authors named "C Braudeau"
Article Synopsis
- Tumor evasion is linked to HHLA2, a new member of the B7 family, often found in PDL-1 tumors, which interacts differently with immune cells by either stimulating or inhibiting them.
- A study compared two monoclonal antibodies targeting CD28H, showing that specific targeting can enhance NK-cell activation and boost their ability to combat cancer cells.
- Analysis of clear cell renal cancer indicated the presence of CD28H NK cells in HHLA2 tumors, suggesting potential for effective treatment using tailored anti-CD28H antibodies.
Article Synopsis
- This pilot study aimed to see if confocal laser endoscopy (CLE) can help identify certain cells (α4β7- and TNF-expressing) that could predict how well ulcerative colitis patients respond to the drug vedolizumab.
- Nineteen patients with moderate-to-severe ulcerative colitis participated, and 58% showed clinical and endoscopic improvement after treatment, with specific staining patterns indicating potential responders versus non-responders.
- The findings suggest that positive α4β7 staining detected through CLE could be linked to better treatment outcomes, although blood tests and immune cell counts did not correlate with patient responses.
Article Synopsis
- Patients with inflammatory bowel disease (IBD) treated with infliximab or vedolizumab showed a COVID-19 prevalence similar to the general French population before vaccinations, with only 4.5% confirmed cases.
- Factors increasing COVID-19 risk included using public transport and living in urban settings, while treatment type or disease activity did not affect infection rates.
- Recommendations suggest that maintaining sanitary barrier measures is essential for IBD patients on biological therapies to minimize the risk of SARS-CoV-2 infection.
OSE-127 is a humanized mAb targeting the IL-7Rα-chain (CD127), under development for inflammatory and autoimmune disease treatment. It is a strict antagonist of the IL-7R pathway, is not internalized by target cells, and is noncytotoxic. In this work, a first-in-human, phase I, randomized, double-blind, placebo-controlled, single-center study was carried out to determine the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of OSE-127 administration.
View Article and Find Full Text PDF